October 8th, 2005 Age-related macular degeneration (AMD) is the leading cause of blindness in older patients in US and the developed world. Pegaptanib sodium (Macugen) is a new treatment for exudative AMD, and has been shown to …
After a comprehensive review of the scientific literature available, Lucentis and Macugen have been endorsed by the American Academy of Ophthalmology as safe and effective treatments for macular degeneration for up to 2 years. In the endorsement it was indicated that there is evidence to support that Macugen and Lucentis as effective treatments. However, there was no endorsement given for Avastin as a treatment for macular degeneration at this time.
In 2007, the board restricted access to two drugs for macular degeneration, a cause of blindness. The drug Macugen was blocked outright. The other, Lucentis, was limited to a particular category of individuals with the disease, …
Of NICE and Men – WSJ.com: “In 2007, the board restricted access to two drugs for macular degeneration, a cause of blindness. The drug Macugen was blocked outright. The other, Lucentis, was limited to a particular category of …
In 2007, the board restricted access to two drugs for macular degeneration, a cause of blindness. The drug Macugen was blocked outright. The other, Lucentis, was limited to a particular category of individuals with the disease, …
